Ascorbic acid infusion blunts CD40L upregulation in patients undergoing coronary stent

Cardiovasc Ther. 2011 Dec;29(6):385-94. doi: 10.1111/j.1755-5922.2010.00168.x. Epub 2010 Jul 12.

Abstract

Objectives: To reduce the increase of oxidative stress and the upregulation of CD40L during stenting procedure using ascorbic acid infusion.

Background: CD40L upregulation occurring after coronary percutaneous coronary intervention predicts vascular events but the underlying mechanism is still unclear.

Methods: Fifty-six patients undergoing elective coronary stenting were randomly allocated to intravenous infusion of the antioxidant ascorbic acid or placebo. Platelet CD40L and plasma levels of soluble CD40L and of 8-hydroxy-2'-deoxyguanosine, a marker of oxidative stress, were measured before and after coronary stenting. In vitro study was also done to measure reactive oxidant species and CD40L expression in platelets exposed to anoxia-reoxygenation.

Results: Placebo-treated patients showed a significant increase of platelet CD40L, soluble CD40L and 8-hydroxy-2'-deoxyguanosine compared to baseline values. Patients given ascorbic acid showed no change of soluble CD40L and platelet CD40L but a significant decrease of 8-hydroxy-2'-deoxyguanosine. After 60 and 120 min, soluble CD40L, platelet CD40L and 8-hydroxy-2'-deoxyguanosine were significantly lower in the ascorbic acid-treated group compared to the placebo-treated one. A significant correlation between platelet CD40L and soluble CD40L and between soluble CD40L and 8-hydroxy-2'-deoxyguanosine was observed. Platelets, in vitro exposed to anoxia-reoxygenation, had a burst of ROS and an upregulation of CD40L that were inhibited by ascorbic acid or apocynin, an inhibitor of NADPH oxidase.

Conclusions: This study shows that in patients undergoing coronary stenting CD40L is upregulated with a mechanism which is likely mediated by oxidative stress.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • 8-Hydroxy-2'-Deoxyguanosine
  • Acetophenones / pharmacology
  • Aged
  • Aged, 80 and over
  • Angioplasty, Balloon, Coronary / adverse effects
  • Angioplasty, Balloon, Coronary / instrumentation*
  • Antioxidants / administration & dosage*
  • Ascorbic Acid / administration & dosage*
  • Biomarkers / blood
  • Blood Platelets / drug effects
  • Blood Platelets / metabolism
  • CD40 Ligand / blood*
  • Coronary Artery Disease / blood
  • Coronary Artery Disease / drug therapy
  • Coronary Artery Disease / therapy*
  • Deoxyguanosine / analogs & derivatives
  • Deoxyguanosine / blood
  • Enzyme Inhibitors / pharmacology
  • Female
  • Flow Cytometry
  • Humans
  • Infusions, Intravenous
  • Italy
  • Linear Models
  • Male
  • Middle Aged
  • NADPH Oxidases / antagonists & inhibitors
  • NADPH Oxidases / metabolism
  • Oxidative Stress / drug effects*
  • Pilot Projects
  • Placebos
  • Prospective Studies
  • Reactive Oxygen Species / metabolism
  • Stents*
  • Time Factors
  • Treatment Outcome
  • Up-Regulation

Substances

  • Acetophenones
  • Antioxidants
  • Biomarkers
  • Enzyme Inhibitors
  • Placebos
  • Reactive Oxygen Species
  • CD40 Ligand
  • 8-Hydroxy-2'-Deoxyguanosine
  • acetovanillone
  • NADPH Oxidases
  • Deoxyguanosine
  • Ascorbic Acid